Gland Pharma Ltd - 543245 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Lakumi Trust Gland Pharma Ltd - 543245 - Compliance Certificate U/R 7(3) Of SEBI (LODR) Regulations, 2015 For The Year Ended 31.03.2024
Compliance Certificate u/r 7(3) of SEBI (LODR) Regulations, 2015 for the year ended 31.03.2024 Gland Pharma Ltd - 543245 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under Reg 74(5) of SEBI (DP) Regulations, 2018 Gland Pharma Ltd - 543245 - Clarification Regarding Increase In Volumes
Clarification regarding increase in volumes Gland Pharma Ltd - 543245 - Clarification sought from Gland Pharma Ltd
The Exchange has sought clarification from Gland Pharma Ltd on April 10, 2024, with reference to Movement in Volume. The reply is awaited.
Two Entities Sell 4.9% Stake In Gland Pharma For Rs 1,411 Crore
Lakumi Trust and Nicomac Machinery have sold a 4.9% stake in Gland Pharma for Rs 1,411 crore through open market transactions. Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Gland Pharma receives approval for Eribulin Mesylate Injection Gland Pharma Ltd - 543245 - Closure of Trading Window
Trading Window of the Company will be closed w.e.f 27.03.2024 until 48 hours of declaration of Audited Financial results for the Quarter and Financial Year ended 31.03.2024 Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation regarding schedule of investor Meet on 26.03.2024 Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of 2,400 Equity Shares on exercise of ESOP